Blood coagulation activation detection reagent as well as preparation method and application thereof

Abstract

The invention relates to the technical field of blood coagulation activation detection, in particular to a blood coagulation activation detection reagent as well as a preparation method and application thereof, and overcomes the defects that in the prior art, a blood coagulation activation detection reagent is poor in stability and more time is consumed during detection, so that the whole detection process is complex and tedious. The blood coagulation activation detection reagent comprises the following components: a Tris buffer solution, heparin, glucosinolate, tea polyphenol and a PEG3000 orPEG6000 stabilizer. According to the invention, the glucosinolate solution arranged in the blood coagulation activation detection reagent is combined with the original Tris buffer solution to preparethe buffer solution, so that the subsequently prepared stabilizer solution, heparin solution and tea polyphenol solution are relatively good in stability, the blood coagulation activation detection work can still be stably, reliably and effectively carried out after long-time storage and transportation, and the use, storage and transportation difficulty of the detection reagent is reduced. The tea polyphenol solution is used, so that the blood coagulation activation detection efficiency can be effectively improved, and the time consumption of the whole detection process is reduced.

Description

technical field [0001] The invention relates to the technical field of blood coagulation activation detection, in particular to a blood coagulation activation detection reagent and its preparation method and application. Background technique [0002] Patients with minor ischemic stroke are at high short-term risk of subsequent stroke, which is likely to result in disability, especially in the first 90 days after stroke. The CHANCE study found that administration of aspirin combined with clopidogrel within 24 hours after minor ischemic stroke or transient ischemic attack (TIA) for 21 days could reduce the risk of stroke recurrence by 32% compared with aspirin alone, and did not increase bleeding complications. The secondary analysis of the POINT study also confirmed that the use of dual-antibody therapy in the first 21 days after the onset of disease has the greatest benefit in reducing ischemic events, and the benefit of continuing to use dual-antibody therapy after 21 days ...

AI Technical Summary

Problems solved by technology

[0003] The mechanism of AR and CR is relatively complicated. Through the detection of drug gene polymorphism combined with TEG to guide antiplatelet medication in patients with acute mild ischemic stroke, and to explore its effectiveness and safety, in order to provide more effective clinical individualized antiplatelet therapy. In the process of guidance, the blood coagulation activation detection step needs to be involved, and the stability of the existing blood coagulation activation detection reagents is poor, and it takes a lot of time to detect, resulting in cumbersome and protracted overall detection process